AstraZeneca to Invest $245 Million in Deal With Cellectis
By Ben Otto
British drugmaker AstraZeneca plans to invest $245 million in a deal with biotechnology company Cellectis to develop next-generation therapeutics in oncology, immunology and rare diseases.
AstraZeneca said Wednesday that it will initially make a $105 million payment to Paris-based Cellectis in the fourth quarter, comprising an $80 million equity investment, for a 22% stake in the company, and $25 million in cash.
AstraZeneca plans to make a further $140 million equity investment, subject to regulatory and other approvals, with a closing in early 2024, taking its total stake in Cellectis to 44%.
AstraZeneca said it plans to leverage Cellectis's gene-editing technologies and manufacturing capabilities to design novel cell and gene therapy products.
Cellectis will be eligible to receive an investigational new drug option fee and various milestone payments ranging from $70 million to up to $220 million for each of 10 candidate products, plus tiered royalties, AstraZeneca said.
AstraZeneca will retain an option for an exclusive license for the products developed under the research collaboration agreement.
Write to Ben Otto at ben.otto@wsj.com
(END) Dow Jones Newswires
November 01, 2023 04:02 ET (08:02 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
The 10 Best Companies to Invest in Now
-
New 4-Star Stocks
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth